EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis

James D Chalmers, Pierre-Régis Burgel, Charles L Daley, Anthony De Soyza, Charles S Haworth, David Mauger, Michael R Loebinger, Pamela J McShane, Felix C Ringshausen, Francesco Blasi, Michal Shteinberg, Kevin Mange und 7 weitere

New England Journal of Medicine · 24.04.2025 · 392 (16) · 1569-1581

DOI: 10.1056/nejmoa2411664 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 24.04.2025. Verfasst von James D Chalmers und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory Medicine and Gastroenterology, University of Dundee, Dundee, United Kingdom. Hauptthemen laut MEDLINE: Bronchiectasis, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 218-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Insmed.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BronchiectasisDipeptidyl-Peptidase IV InhibitorsAdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultDisease ProgressionDose-Response Relationship, DrugDouble-Blind MethodForced Expiratory VolumeQuality of LifeDrug Administration ScheduleAdministration, OralNeutrophilsKeratosisTreatment OutcomeAged, 80 and overBenzoxazoles

Substanzen

Dipeptidyl-Peptidase IV InhibitorsBenzoxazolesOxazepinesbrensocatib

Autor:innen und Institutionen

  • Division of Respiratory Medicine and Gastroenterology, University of Dundee, Dundee, United Kingdom.
  • Hôpital Cochin and Cystic Fibrosis National Reference Center, Service de Pneumologie, Assistance Publique-Hôpitaux de Paris, Paris.
  • Université Paris Cité, INSERM Unité 1016-Institut Cochin, Paris.
  • National Jewish Health, Denver.
  • University of Colorado, Denver.
  • Population and Health Sciences Institute, NIHR Biomedical Research Centre for Aging, Newcastle University, Newcastle upon Tyne, United Kingdom.

Förderung

  • Insmed

Zitieren

APA

Chalmers, J. D., Burgel, P. R., Daley, C. L., De Soyza, A., Haworth, C. S., Mauger, D., Loebinger, M. R., McShane, P. J., Ringshausen, F. C., Blasi, F., Shteinberg, M., Mange, K., Teper, A., Fernandez, C., Zambrano, M., Fan, C., Zhang, X., Metersky, M. L., & ASPEN Investigators (2025). Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. New England Journal of Medicine, 392(16), 1569-1581. https://doi.org/10.1056/nejmoa2411664

Vancouver

Chalmers JD, Burgel PR, Daley CL, De Soyza A, Haworth CS, Mauger D, et al. Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. New England Journal of Medicine. 2025;392(16):1569-1581. doi:10.1056/nejmoa2411664

BibTeX
@article{Chalmers2025,
  author = {Chalmers, James D and Burgel, Pierre-Régis and Daley, Charles L and De Soyza, Anthony and Haworth, Charles S and Mauger, David and Loebinger, Michael R and McShane, Pamela J and Ringshausen, Felix C and Blasi, Francesco and Shteinberg, Michal and Mange, Kevin and Teper, Ariel and Fernandez, Carlos and Zambrano, Migdalia and Fan, Chunpeng and Zhang, Xiangmin and Metersky, Mark L and ASPEN Investigators, ASPEN Investigators},
  title = {Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {16},
  pages = {1569--1581},
  doi = {10.1056/nejmoa2411664}
}
Kostenlos starten →